Myelodysplastic syndromes (MDS) are overwhelmingly caused by acquired genetic damage rather than inherited mutations. In roughly nine out of ten patients, the disease traces to somatic mutations that accumulate in blood-forming stem cells over a lifetime, driven by aging, environmental exposures, or prior cancer treatment. A smaller but growing share of cases, particularly in children and younger adults, can be linked to inherited germline variants that predispose someone to MDS from birth. The distinction between acquired and inherited risk matters for treatment, family screening, and transplant decisions, and it is rarely as simple as either-or.
How Acquired Mutations Drive Most MDS
The genetic underpinning of MDS is, for most patients, something that develops during life rather than something present at birth. Systematic sequencing of MDS genomes has identified more than 40 genes that are recurrently mutated, and collectively these mutations show up in close to 90% of patients. The affected pathways include the machinery that reads and copies RNA (splicing), the chemical tags that turn genes on and off (DNA methylation and chromatin modification), transcription factors, cell signaling, and the cell cycle checkpoint controlled by TP53. Most patients carry two or more of these mutations at the time of diagnosis, and specific combinations tend to travel together or avoid each other, suggesting they interact during disease development.1Blood. Myelodysplastic Syndromes: Beyond the Karyotype and Blast Count Somatic Mutations in Myelodysplastic Syndrome
These mutations are somatic, meaning they arise in a single blood stem cell and then spread as that cell divides and its descendants take over a larger share of the bone marrow. They are not present in egg or sperm cells and cannot be passed to children. The mutational burden reflects decades of cell division, DNA copying errors, and environmental insults, which is why MDS is far more common in older adults. In a mouse model of sickle cell disease, accelerated stem cell turnover led to a measurably higher load of the age-related mutation signatures (C>T and G>A changes) and an increased incidence of myelodysplasia, reinforcing the link between replicative stress and MDS development.2Blood. Replicative stress-induced aging of hematopoietic stem progenitor cells increases oncogenic mutation burden and incidence of myelodysplasia in sickle cell disease mice
Clonal Hematopoiesis as a Precursor Step
Before MDS becomes a diagnosable disease, many people carry an intermediate state called clonal hematopoiesis of indeterminate potential (CHIP). In CHIP, a blood stem cell has picked up one or more of the same mutations seen in MDS, but the person still has normal blood counts and no symptoms. CHIP becomes increasingly common with age, detectable in a sizable fraction of people over 70. The key reassurance is that CHIP progresses to a full-blown blood cancer at a rate of only about half a percent to 1% per year, roughly comparable to the rate at which other pre-malignant conditions (like monoclonal gammopathy) transform. People with larger mutant clones face a proportionally higher risk of progression.3PubMed Central. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
CHIP’s existence blurs the line between “normal aging” and “early disease.” It also explains why therapy-related MDS can appear seemingly soon after chemotherapy: in many cases, the mutant clone was already present, and the cytotoxic treatment gave it a growth advantage by wiping out competing normal stem cells. This connection between pre-existing clonal hematopoiesis and later MDS development after cancer treatment has become a major research focus.4PubMed. Clonal Hematopoiesis and therapy related MDS/AML
When MDS Really Is Inherited
A minority of MDS cases stem from inherited germline variants, and this fraction is larger than previously appreciated, especially in children. Cohort studies of pediatric MDS have found that anywhere from 7% to 31% of patients carry germline variants in genes that predispose to the disease. The two most common inherited drivers are GATA2 deficiency and SAMD9/SAMD9L syndromes. Together, these account for roughly 15% of primary pediatric MDS cases. GATA2 variants alone make up about 7% of all pediatric MDS and roughly 15% of the more advanced subtypes. SAMD9/SAMD9L syndromes tend to show up in preschool-aged children, often triggered after an infectious illness.5Haematologica. Germline and somatic genetic landscape of pediatric myelodysplastic syndromes
Beyond GATA2 and SAMD9/9L, several classical bone marrow failure syndromes carry a well-established MDS risk. Fanconi anemia, caused by defects in DNA repair genes within the FA/BRCA pathway, predisposes patients to bone marrow failure, MDS, acute myeloid leukemia (AML), and solid tumors.6PubMed. Classical inherited bone marrow failure syndromes with high risk for myelodysplastic syndrome and acute myelogenous leukemia Dyskeratosis congenita, which involves defective telomere maintenance, is another inherited syndrome linked to MDS and AML.7Blood. Immunoglobulin and Lymphocyte Subset Abnormalities in Patients with Fanconi Anemia and Dyskeratosis Congenita What makes the picture more complex is that even carrying just one mutated copy of a Fanconi anemia gene, rather than the two copies needed for the full syndrome, may not be completely protective. A large sequencing study of 489 patients with bone marrow failure detected an increased frequency of heterozygous (single-copy) Fanconi anemia gene mutations in MDS patients, suggesting these variants may have a long latency before causing trouble.8PubMed Central. Fanconi Anemia germline variants as susceptibility factors in aplastic anemia, MDS and AML
Other germline genes now recognized as MDS risk factors include DDX41, RUNX1, CEBPA, ETV6, and several others that have been added to classification systems in recent years. The recognition of these inherited predispositions has changed guidelines: newly diagnosed children and adults with MDS should now be screened for the presence of a genetic predisposition syndrome because the results can reshape clinical care for both the patient and their family members.9Seminars in Hematology. Practical considerations for diagnosis and management of patients and carriers
Environmental and Occupational Exposures
Among acquired risk factors, chemical exposures stand out. Benzene is the best-documented environmental cause of MDS. A population-based study found that benzene exposure roughly doubled the odds of MDS, and the risk climbed with longer and heavier exposure. Vinyl chloride showed a similar association.10PubMed Central. Chemical Exposures and Risk of Acute Myeloid Leukemia and Myelodysplastic Syndromes in a Population-Based Study An international pooled analysis of petroleum workers, where benzene exposure was carefully measured, found a clear dose-response relationship: those with the highest cumulative exposure had more than four times the odds of MDS compared to the least-exposed workers, and peak exposures above 3 parts per million raised the odds even further.11PubMed Central. Myelodysplastic Syndrome and Benzene Exposure Among Petroleum Workers: An International Pooled Analysis
The relevant exposure window appears to be the years leading up to diagnosis, not necessarily decades before. A study of Chinese workers with occupational benzene exposure emphasized the period roughly two to ten years before diagnosis as the most informative time frame for risk.12JNCI: Journal of the National Cancer Institute. Benzene Exposure Response and Risk of Myeloid Neoplasms in Chinese Workers: A Multicenter Case–Cohort Study People with current or recent occupational exposure to petroleum products, solvents, paints, or certain manufacturing chemicals should be aware of this link.
Therapy-Related MDS
Prior cancer treatment is one of the strongest acquired risk factors for MDS. Therapy-related MDS (t-MDS) develops after exposure to chemotherapy, radiation, or both, and tends to carry a worse prognosis than MDS that arises on its own. The underlying mechanism involves direct DNA damage from cytotoxic drugs and radiation, which both introduces new mutations and provides a selective advantage to stem cells that already carry them.4PubMed. Clonal Hematopoiesis and therapy related MDS/AML
At the epigenetic level, cytotoxic drugs and radiation have been shown to alter DNA methylation patterns in ways that promote cancer development. Radiation can induce stable, widespread loss of methylation (hypomethylation), while specific gene promoters can become abnormally silenced by gaining too much methylation (hypermethylation). In therapy-related MDS, promoter hypermethylation of genes that control cell division, programmed cell death, and DNA repair is significantly more frequent than in MDS that arises without prior treatment, suggesting that epigenetic disruption is an important piece of the secondary leukemogenesis puzzle.13PubMed. Epigenetic changes in therapy-related MDS/AML
Smoking and Lifestyle Factors
Smoking adds a measurable layer of genetic damage to the MDS picture. In a study that compared smokers and non-smokers with MDS-spectrum conditions, the total number of mutations looked similar on the surface. But after adjusting for age, sex, and disease subtype, smokers actually carried more mutations on average. The relationship followed a dose-response pattern: heavier smokers, measured in pack-years, had progressively more mutations. Patients at the 90th percentile of smoking exposure had roughly three and a half times the mutation burden of non-smokers. Specific gene pathways involved in chromatin modification and RNA splicing were particularly affected.14Blood. Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes
This finding is consistent with what is known about smoking and blood cancers more broadly, but it adds a level of specificity: smoking does not just raise the overall odds of MDS, it appears to accelerate the accumulation of the exact mutations that define the disease. For someone who already has MDS or a precursor condition like CHIP, this is worth taking seriously as a modifiable risk factor.
The Bone Marrow Microenvironment
MDS is not purely a disease of the blood-forming cells themselves. The bone marrow microenvironment, the supporting tissue that surrounds and nourishes stem cells, shows its own abnormalities. In a study examining samples from 106 patients across a range of MDS subtypes, the mesenchymal stromal cells (a key support cell population) had reduced ability to differentiate into bone-forming osteoblasts. This was confirmed by decreased expression of osteogenesis-related genes and lower levels of a bone-building protein (osteocalcin) in patients’ blood. The defect was present across all MDS subtypes, suggesting that the “soil” of the bone marrow is abnormal alongside the “seeds” of the mutant stem cells.15PubMed Central. The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression
Inflammation is another microenvironmental driver. Aberrant activation of the innate immune system, including an inflammatory complex called the NLRP3 inflammasome, has been identified as a key pathogenic force in MDS. Somatic mutations of varied types converge on this inflammatory pathway, producing excess reactive oxygen species, abnormal cell swelling, and activation of cell-death enzymes. The inflammatory bone marrow environment appears to both promote the growth of mutant clones and suppress normal blood cell production, contributing to the low blood counts that define the disease.16PubMed Central. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes
How Genetic Differences Shape Prognosis
Once MDS is diagnosed, the specific constellation of mutations a patient carries has profound implications for prognosis and treatment. The Molecular International Prognostic Scoring System (IPSS-M), developed using data from thousands of patients, incorporates mutations in 31 genes alongside blood counts and chromosomal abnormalities to assign each patient a unique risk score across six categories. Compared to older scoring systems that relied mainly on blood counts and chromosomal analysis, the IPSS-M reclassified about 46% of patients, many of them into higher-risk groups than their previous staging suggested.17PubMed. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
Validation in an independent cohort confirmed these results: roughly 42% of patients were reclassified and about 29% were upstaged, meaning their disease was more aggressive than older tools indicated. For nearly 17% of patients, the reclassification would have changed their recommended treatment approach.18Blood Cancer Journal. Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification In practical terms, this means genetic profiling at diagnosis is no longer optional: it directly determines whether someone is offered watchful waiting, drug therapy, or a stem cell transplant.
Progression From MDS to Leukemia
MDS and AML secondary to MDS exist on a genetic continuum. Both diseases harbor mutations in the same genes and functional categories, but the frequency of specific mutations shifts during progression. Disease advancement almost always involves clonal evolution: a subclone carrying additional mutations expands and takes over the bone marrow. Mutations in FLT3, RAS, and especially TP53 appear at higher rates in secondary AML than in MDS alone. TP53 mutation is itself an independent predictor of poor outcomes when MDS transforms to AML.19PubMed Central. Secondary Acute Myeloid Leukemia in Myelodysplastic Syndrome Patients Aged Over 60 Years20Blood. Genetics of progression from MDS to secondary leukemia
The order of mutation acquisition during this progression is not random. Founding mutations in genes like TET2, DNMT3A, or splicing factors typically appear first, while signaling pathway mutations and additional TP53 hits come later. Understanding this sequence helps clinicians identify patients at higher risk of transformation and may eventually guide the timing of interventions.
Genetic Testing Practicalities
If germline testing is recommended, the choice of tissue sample matters more than many patients realize. Blood and bone marrow are poor choices for confirming whether a mutation is inherited, because the cancer cells circulating in those samples may carry acquired mutations that look identical to germline ones. The preferred source is cultured skin fibroblasts from a skin biopsy. Hair follicles and nail clippings can also work, though getting enough DNA from them can be challenging. Buccal (cheek) swabs require cautious interpretation because of contamination with circulating blood cells.21American Journal of Clinical Pathology. How I diagnose myeloid neoplasms with germline predisposition
The emotional weight of germline testing should not be underestimated. A positive result means the mutation could have been inherited by children, siblings, or other relatives, which raises questions about cascade testing, reproductive decisions, and long-term surveillance. Genetic counselors play a central role in navigating these conversations, helping patients weigh the implications for family relationships and psychological well-being alongside the medical facts.22PubMed Central. Genetic Predisposition to Myelodysplastic Syndrome: Genetic Counseling and Transplant Implications
Transplant Decisions and Donor Selection
Germline MDS predisposition genes carry unique consequences for stem cell transplantation, the only curative therapy for most MDS patients. When a patient has a germline variant in genes like GATA2, DDX41, RUNX1, or CEBPA, related family members who might otherwise serve as donors could carry the same variant. Using such a donor risks transferring the genetic predisposition into the recipient, potentially leading to donor-derived leukemia. Studies have also shown that donors carrying these variants may have trouble mobilizing enough stem cells or that the transplanted cells may fail to engraft properly.23PubMed Central. Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant
Current guidelines recommend that when a germline variant linked to MDS is identified, an automatic search for unrelated donors should be initiated, even if suitable siblings appear to be available. This avoids the risk of unknowingly selecting a family donor who carries the same predisposition.24The Lancet Haematology. Exploring guidelines for genetic testing and predisposition for MDS in the context of alloHCT The practical consequence is that germline testing should ideally happen early enough to allow time for an unrelated donor search if needed.
Targeted Therapies Shaped by Mutation Profiles
The expanding catalog of MDS-associated mutations has opened the door to treatments aimed at specific molecular targets. TP53 mutations, which confer some of the worst outcomes in MDS with median survival often under a year, have shown responsiveness to a combination of eprenetapopt and azacitidine, with an overall response rate around 73% in early trials. IDH1/2 inhibitors, already approved in AML, have demonstrated durable responses in patients with the corresponding mutations; ivosidenib, for example, achieved an overall response rate of about 83% with median survival extending past three years in one dataset.25PubMed Central. Hotspot gene mutations and treatment response in myelodysplastic syndromes (MDS): predictive biomarkers and targeted strategies
Many other pathways are under investigation. Splicing factor mutations, signaling pathway alterations, and inflammatory drivers are all being evaluated as therapeutic targets, with a growing pipeline of drugs in early and mid-stage clinical trials.26PubMed Central. Treatments targeting MDS genetics: a fool’s errand? – Section: Using somatic mutations to consider targeted therapy The broader point is that the genetic profile of a patient’s MDS is not just a prognostic curiosity. It increasingly determines which drugs are offered and which are likely to work.
Ancestry and the Mutation Landscape
The genetic mutations that drive MDS are not distributed equally across population backgrounds. In a study of 1,680 ancestry-typed MDS patients, researchers found that genetic ancestry shaped mutation prevalence in ways that self-reported race alone did not capture. DNMT3A mutations, one of the most common MDS-associated changes, were about 1.7 times more frequent in patients with Ashkenazi Jewish ancestry compared to those with European ancestry. TET2 mutations were significantly less common in patients with admixed American ancestry. Patients with African ancestry showed a lower frequency of U2AF1 and TP53 mutations, directionally consistent with patterns previously reported in AML.27Clinical Lymphoma, Myeloma and Leukemia. Genetic Ancestry Shapes Mutation Prevalence in MDS Patients Beyond Self-Reported Race
These differences likely reflect a combination of inherited genetic background influencing which somatic mutations are tolerated or selected for, and possibly environmental or lifestyle exposures that vary by population. For clinical practice, the implication is that risk models developed primarily in European-ancestry populations may not perform identically in other groups, and molecular profiling of individual patients matters more than demographic assumptions.
Non-Coding RNA and Emerging Layers of Regulation
Research is also looking beyond the protein-coding genes where most MDS mutations are found. Non-coding RNAs, particularly microRNAs and long non-coding RNAs, regulate blood cell production and have been implicated in the development of blood cancers. These molecules do not carry the instructions for building proteins, but they fine-tune how other genes are expressed, acting as volume dials on the activity of dozens of target genes at once.28PubMed Central. The Role of Non-Coding RNAs in Myelodysplastic Neoplasms This is still a relatively early field in MDS, but it suggests that some aspects of the disease’s genetics may involve subtler regulatory changes that current diagnostic panels do not routinely capture. As sequencing technology becomes more comprehensive and cheaper, these layers of information may eventually contribute to risk stratification and treatment decisions alongside the now-standard somatic mutation panels.